Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane + OFS vs Tamoxifen + OFS in CYP2D6*10 Mutated Breast Cancer
NCT03137368Phase 3Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2018
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane in breast cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Disease Free Survival at 5 years. Status: unknown.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03137368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137368.